A worrisome scarcity of cancer drugs has heightened concerns about the troubled generic drug industry. Congress and the White House are seeking ways to address widespread supply problems.
Author: Christina Jewett
FDA’s Drug Industry Fees Fuel Concerns Over Influence
The pharmaceutical industry finances about 75 percent of the agency’s drug division, through a controversial program that Congress must reauthorize by the end of this month.
F.D.A. Clears Path for Over-the-Counter Hearing Aids
The agency’s action opens the door to cheaper, more accessible devices without a prescription or medical exam.
The F.D.A.’s budget proposal aims to prepare for another pandemic.
F.D.A.’s Accelerated Drug Approvals Come Under Scrutiny
A drug to prevent preterm birth may provide the next test of the agency’s process for speedily getting drugs on the market, despite limited evidence that some work.
Senate Panel OKs Califf Nomination for F.D.A. Chief
A key committee was split mainly on party lines over the nomination of Dr. Robert Califf, foreshadowing divisions in the full Senate for a vote on confirmation.
Senators Question Califf, the F.D.A. Nominee, on Opioid Crisis and Pandemic Response
A Senate panel hearing on Tuesday signaled that Dr. Robert Califf, who briefly led the agency during the Obama administration, had some bipartisan support.